Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lttl vs NexLife

Lttl
Graded #204

Lower grade

vs+2.6000000000000085
NexLife
Graded #139

Higher grade

The verdict

NexLife takes it — 68.7/100 to 66.1/100.

NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNexLife +15
56
71
Dose & formulationLttl +32
96
64
Clinical oversightNexLife +13
76
89
Labs & monitoringNexLife +1
52
53
FulfillmentLttl +2
69
67
Contract termsNexLife +35
20
55
Lttl · left barNexLife · right bar

The numbers

MetricLttlNexLife
WeighScore66.1/10068.7/100
GradeCC
Scorecard rank#204#139
Semaglutide$199/mo (all doses, compounded)$165/mo (compounded)
Tirzepatide$279/mo (all doses, compounded)$215/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Lttl

Graded #204 · C

Strengths

  • Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
  • Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
  • States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
  • Oral ODT semaglutide offered for members who want to avoid injections

Where it loses points

  • Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
  • The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
  • No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
  • Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
  • Medications cannot be returned or refunded once they ship from the pharmacy
NexLife

Graded #139 · C

Strengths

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

Where it loses points

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard